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Background: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma
(mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study
was to evaluate the efficacy and safety of axitinib as first-line therapy in Japanese patients with locally advanced
RCC or mRCC.
Methods: In this retrospective study, we focused on eighteen patients who underwent first-line therapy with
axitinib between May 2012 and May 2014 at Hirosaki University. Axitinib was orally administered at a dose of
10 mg daily. Progression-free survival (PFS) was the primary endpoint, while secondary endpoints included
overall response rate (ORR) and adverse events (AEs).
Results: All patients had histologically proven clear cell RCC. The median duration of the administration of
axitinib was 10.8 months. According to the response evaluation criteria for solid tumors, five patients (27.8%)
achieved a partial response and nine (50%) had stable disease. The 1-year PFS rate was 84.4%, and the median
PFS was 20.4 months (95% confidence interval, 17.5 – 21.7). No serious AEs were reported during the study,
and there were no toxicity-related deaths.
Conclusions: In the current study, axitinib showed acceptable oncological outcomes and favorable safety profile as
first-line therapy for locally advanced RCC or mRCC in treatment-naïve Japanese patients. Thus, first-line therapy with
axitinib may provide a feasible option for treatment of advanced RCC or mRCC patients.
Keywords: Axitinib renal cell carcinoma, First-line, Vascular endothelial growth factor receptor, Advanced renal cell
carcinoma, Metastatic renal cell carcinomaBackground
Although the innate chemoresistance of renal cell car-
cinoma (RCC) is a limitation in the systemic treatment
for metastatic renal cell carcinoma (mRCC) [1], the clin-
ical benefits of using targeted agents to treat patients
with mRCC or locally advanced RCC have become in-
creasingly clear [2]. Currently, six targeted agents are ap-
proved for the treatment of mRCC in Japan, including
the multi-targeted receptor tyrosine kinase inhibitors
(TKIs): sunitinib, pazopanib, axitinib and sorafenib; and* Correspondence: coyama@cc.hirosaki-u.ac.jp
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unless otherwise stated.the mammalian target of rapamycin inhibitors (mTORs):
everolimus and temsirolimus.
There is no doubt that initial treatment of low- or
intermediate-risk mRCC patients [3] with a vascular
endothelial growth factor (VEGF)-targeted agent sig-
nificantly improves clinical outcomes compared with
conventional immunotherapy [4]. Of these, sorafenib,
sunitinib and pazopanib have been approved as first-line
treatment for advanced RCC or mRCC based on several
clinical trials conducted in Western countries [2-4].
Similarly, first-line therapy with temsirolimus has dem-
onstrated efficacy in patients with poor-risk mRCC [3,5].
However, based on the incidence and severity of adverse
events (AEs) in several clinical trials [6-9], Japaneseis is an Open Access article distributed under the terms of the Creative
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AEs to TKIs compared with their Western counterparts.
Axitinib, an effective and selective second-generation
inhibitor of VEGF receptors-1, 2, and 3 [10], has demon-
strated clinical efficacy in patients with mRCC in phase
II studies [11,12]. Single-agent axitinib is active and well
tolerated as a second-line treatment for mRCC [11,12].
Conversely, no significant increase in progression-free
survival (PFS) was found in treatment-naïve mRCC pa-
tients who were treated with axitinib, when compared
with those treated with sorafenib [13]. However, it is
possible that Japanese patients may exhibit a different
response to axitinib, in terms of antitumor effects or
profile of AEs, when compared with their Western
counterparts [14]. In the National Comprehensive Can-
cer Network guideline 2015, axitinib is recommended as
a treatment option for first-line therapy in patients with
locally advanced or metastatic RCC.
This study, which was carried out at a single institu-
tion in Japan, aimed to evaluate the efficacy and safety of




In this retrospective study, we reviewed the clinical and
pathological records of a total of 39 locally advanced
RCC or mRCC patients who were administered VEGFR-
TKIs or mTORs between May 2012 and May 2014 at
Hirosaki University. We focused on 18 patients who
underwent first-line therapy with axitinib. Eligible pa-
tients had histologically confirmed clear cell RCC, with
local progression or distant metastases. Data on patient
demographics and tumor characteristics were obtained
from the patients’ medical charts. Memorial Sloan-
Kettering Cancer Center (MSKCC) criteria were evaluated
based on the five risk factors: low Karnofsky performance
status (<80), high LDH (>1.5 times the upper limit of nor-
mal), low serum hemoglobin, high corrected serum cal-
cium (>10 mg/dL), and time from initial diagnosis to
axitinib treatment of <1 year [3].
The study protocol and informed consent documents
were reviewed and approved by the Hirosaki University
institutional review board.
Treatment
Axitinib was administered orally at a dose of 10 mg
daily. The axitinib dose was reduced in patients with
grade 3 AEs based on the Common Terminology Cri-
teria for Adverse Events (version 4) or two readings of
systolic blood pressure at 150 mmHg or higher, or dia-
stolic blood pressure at 100 mmHg or higher, while
maintaining maximal antihypertensive therapy. In thisstudy, none of the patients received axitinib dose
titration.
Patient evaluation
Based on the results of percutaneous ultrasonography-
guided biopsy, the diagnosis of RCC was confirmed by a
single pathologist at our institution.
Baseline evaluations included complete history-taking
and physical examinations, assessment of Eastern Co-
operative Oncology Group performance status (ECOG
PS), abdominal and pelvic computed tomography (CT)
or magnetic resonance imaging (MRI), and chest radiog-
raphy or CT. Tumors were measured at baseline before
the administration of axitinib. The response to treatment
was assessed using the Response Evaluation Criteria in
Solid Tumors, version 1.1 [15]. Bone lesions were con-
sidered non-measurable.
All tumors were staged according to the cancer staging
manual (7th edition), published by the American Joint
Committee on Cancer [16].
Endpoints and statistical analysis
The primary endpoint was the PFS. The secondary end-
points were overall response rate (ORR) and AEs. The
PFS was defined as the time between the initiation of
axitinib treatment and the date on the CT scan that
identified progressive disease (PD), on other records of
clear clinical evidence of PD, or death.
Data were analyzed using IBM SPSS Statistics 20 (IBM
Corp., Armonk, NY, USA). Survival after axitinib admin-
istration was estimated using the Kaplan–Meier method.
All P values were 2-sided, and the significance level was
set at a P value of < 0.05.
Results
Patient characteristics and treatment
The pretreatment characteristics of the patients are
listed in Table 1. All patients had histologically proven
clear cell RCC. The median duration of the administra-
tion of axitinib was 10.8 months. Seven patients received
reduced axitinib dosing. Five patients received a con-
tinuous reduced dose of 3 mg twice daily; of these pa-
tients, four had exhibited systolic blood pressure of
150 mmHg or higher, one had suffered general malaise,
and one had developed grade 3 proteinuria. Two pa-
tients received a continuous reduced dose of 1 mg twice
daily due to general malaise.
Clinical response and PFS
According to the response evaluation criteria in solid tu-
mors (RECIST) criteria, five patients achieved a partial
response, nine had stable disease, and four had PD. Me-
dian duration of response was 10.8 months (interquartile
range [IQR], 5.6-18.3). Tumor shrinkage was observed
Table 1 Patient characteristics
Variable Value













Site of metastasis, number (%)
None 5 (27.8)
Lung 5 (27.8)
Lymph node 4 (22.2)
IVC thrombus 4 (22.2)
Bone 2 (11.1)
Liver 1 (5.6)
Prior to nephrectomy, number (%) 4 (22.2)
Follow-up period (months), median (IQR) 11.5 (5.1–17.4)
* Risk groups are stratified in accordance with the Memorial Sloan-Kettering
Cancer Center (MSKCC) criteria associated with shorter survival based on five
risk factors: low Karnofsky performance status (<80%), high LDH (>1.5 times
the upper limit of normal), low serum hemoglobin, high corrected serum calcium
(>10 mg/dL), and interval of <1 year between initial diagnosis and axitinib
treatment [3]
ECOG PS, Eastern Cooperative Oncology Group performance status; IVC,
inferior vena cava
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metastatic site in 5 patients), with a median decrease of
20% in tumor size (IQR, 4.7–33.5; Figure 1).
Three patients underwent open radical nephrectomy
after axitinib treatment. Median operative time was
100 minutes (range: 95–128); the median estimated
blood loss was 225 mL (range: 50–380 mL). No intraop-
erative or postoperative complications, as defined by the
Clavien-Dindo classification [17], were encountered. The
kidney was noted to be adherent to surrounding tissues,
including the peritoneum, in all three cases. Pathological
examination on final nephrectomy specimens confirmed
the presence of clear cell RCC in all three patients;
pathological stages were further diagnosed as pT1b,
pT3a, and pT3b.
At the end of the follow-up period, none of the pa-
tients had died of cancer or other causes. The 1-year
PFS rate was 84.4% (Figure 2). The median PFS was
20.4 months (95% confidence interval, 15.8–21.5). The1-year PFS rate was 55.6% in the patients with locally
advanced RCC (locally advanced group) and 100% in the
patients with metastasis (metastasis group) (P = 0.373).
The median PFS was not reached in the locally advanced
group, and it was 20.4 months in the metastasis group.
According to the MSKCC risk stratification, the PFS did
not differ significantly among all risk groups (P = 0.985).
Two patients received sunitinib as a second-line treat-
ment, and one patient underwent third-line therapy with
pazopanib. One patient received best supportive care.
The duration of effectiveness in the patients who were
administered sunitinib or pazopanib as second-line treat-
ment were 3 and 6 months, respectively.
Safety of axitinib treatment
The AEs are shown in Table 2. Hypertension was the
most frequent AE. Grade 3 proteinuria was observed in
two patients. Other toxicities were infrequent and mild.
No serious grade 4 AEs were reported during the study,
and there were no toxicity-related deaths.
Discussion
Till 2005, the standard of care was limited to cytokine
therapy, including interferon-alpha (IFN-α) and/or
interleukin-2, and these treatments were frequently asso-
ciated with limited efficacy and high toxicity [18]. A bet-
ter understanding of the molecular mechanisms that
target angiogenesis by direct inhibition of VEGF or
mTOR has led to improved treatment options for RCC.
Clinical trials using novel targeted agents, including
TKIs or mTORs, have been evaluated in large random-
ized controlled studies conducted in both the first- and
second-line setting [19]. Of these, sunitinib demon-
strated superior efficacy to IFN-α as first-line mRCC
therapy, with a median PFS of 11 versus 5 months (P <
0.001), respectively, in a randomized phase III trial [4].
Sunitinib is currently regarded as the reference standard
of care for the first-line treatment of mRCC.
Several studies have reported widely variable rates and
grades of sunitinib-related AEs [6,8,9,20]. The rates of
incidence for the most common grade 3/4 AEs that re-
quire dose discontinuation and/or reduction, including
hand-foot syndrome (HFS), stomatitis, and hypertension
were similar to the rates reported in previous trials
[21,22]. However, differences in ethnicity-based treat-
ment tolerance may have also played a role. Miyake
et al. reported that the rates of incidence of AEs ≥ grade
3 in a phase III clinical trial and a phase II Japanese clin-
ical trial were 61% and 95%, respectively [9]. Similarly, ad
hoc analyses indicate that several AEs occur at a signifi-
cantly higher rate in Asian patients relative to Caucasian
patients; for example, HFS occurred in 70% of Asian pa-
tients compared with 28% of Caucasian patients (P <
0.001) [8]. Although the standard sunitinib schedule
Figure 1 Waterfall plot showing tumor response to axitinib by RECIST. Bars represent individual evaluable patients. Gray, partial response; black,
stable disease.
Figure 2 Kaplan-Meier analysis of progression-free survival. The 1-year progression-free survival rate was 84.4% (95% confidence interval, 15.8-21.5).
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Table 2 Adverse events
Adverse events Any grade, number (%) Grade 3, number (%)
Hypertension 7 (38.9) 1 (5.6)
Proteinuria 5 (27.8) 2 (11.1)
Hypothyroidism 3 (16.7) 0
General malaise 3 (16.7) 0
Hand-foot syndrome 2 (11.1) 0
Anemia 1 (5.6) 0
Stomatitis 1 (5.6) 0
Renal impairment 1 (5.6) 0
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modified schedule of sunitinib treatment, with two weeks
of treatment and one week of rest, was associated with
significantly decreased toxicity [23].
Common AEs of axitinib include diarrhea, hyperten-
sion, fatigue, anorexia and weight loss. The safety profile
of axitinib is generally manageable with standard med-
ical intervention [24]. In the AXIS study, discontinuation
rates due to treatment-related AEs were 4% in the axi-
tinib arm and 8% in the sorafenib arm, while dose inter-
ruptions and reductions were required in 77% and 31%
of axitinib recipients [25]. The AXIS study protocol
allowed for dose escalation in the absence of hyperten-
sion or grade 2 AEs, which may have been partially re-
sponsible for the subsequent increase in dose-reduction
rate [26].
In this study, the treatment-naïve cRCC patients had
a relatively longer PFS without axitinib dose titration,
compared with other clinical trials. Rini et al. reported
that in treatment-naïve mRCC patients who initially tol-
erated axitinib at a dose of 5 mg twice daily, a signifi-
cantly higher proportion achieved an objective response
with axitinib dose titration than with placebo titration
[27]. Furthermore, based on the results from a phase 3
trial evaluating axitinib versus sorafenib in treatment-
naïve patients with mRCC, the median PFS was
10.1 months with axitinib and 6.5 months with sorafenib
(P = 0.038) [13]. In addition, median PFS was
13.7 months with axitinib and 6.6 months with sorafenib
in patients with ECOG PS 0 (P = 0.022) [13]. In this
study, the differences in PFS were not significant be-
tween all risk groups, according to the MSKCC risk
stratification. Although brief exposure to higher axitinib
doses may achieve immediate tumor shrinkage, a sub-
stantial proportion of patients may subsequently be
forced to lower axitinib doses, which may lead to lower
rates of long term disease control.
The current study has several limitations. First, it is a
retrospective study, with an inherent potential for bias.
Second, a relatively small number of patients were en-
rolled in this study, and the follow-up period wasrelatively short. In this study, the number of enrolled
patients was relatively high age compared with other
randomized trials [13,27]. AEs were also effectively man-
aged with medications or axitinib dose reduction in this
study. Although a large proportion of patients in other
randomized control studies were recruited from North
America and Western Europe, some patients were re-
cruited from Asia, but the number was not large
enough. Therefore, axitinib as first-line therapy may pro-
vide a treatment option for selected Japanese patients
with locally advanced or mRCC.
Conclusions
In the current study, axitinib showed improved onco-
logical outcomes and an acceptable safety profile as the
first-line therapy for advanced RCC or mRCC in
treatment-naïve patients. Thus, first-line therapy with
axitinib may provide a promising treatment option for
advanced RCC or mRCC patients. Further trials in the
first-line setting are warranted.
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